{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-356915","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2026-08-19T20:15:13+00:00","discovered_at":"2026-08-19T20:16:00.291497+00:00","generated_at":"2026-08-19T20:16:09.120397+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Jaguar Health Q2 2026 revenue down 59% YoY; net loss widens to $12.7M","bullets":["Total net revenue $1.225M vs $2.979M in Q2 2025 (-59%); product revenue down 60% to $1.18M.","Net loss attributable to common stockholders $12.69M vs $10.41M; EPS -$15.68 vs -$358.94.","Sales/marketing expense fell $2.5M after Future Pak licensing Jan 12, 2026; cost of product revenue rose to ~$1.0M.","MVID NDA package expected ready end-2026; submission planned Q2 2027; crofelemer MVID data showed parenteral support reduction up to 48%.","Non-GAAP recurring EBITDA loss widened to $8.4M; loss on debt extinguishment $3.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-356915","json":"https://secwatch.observer/filing/0001193125-26-356915.json","markdown":"https://secwatch.observer/filing/0001193125-26-356915.md","text":"https://secwatch.observer/filing/0001193125-26-356915.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526356915/0001193125-26-356915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526356915/d380271d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-19T20:16:09.120397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}